Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.

With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.

Forty years ago, it was theorized that chirality had a color composition that could be measured… and finally the theory has been proven.

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

If you or your supplier are working with animal-derived components, you run the risk of exposing patients to dangerous contaminations.

When considering the elderly, we can’t stop at drug development – packaging needs special consideration too.

Meet the analytical experts working at the cutting-edge of pharma analytics to ensure the safety of medicines.

A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines.

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Struggling with process research and development? Find yourself a CRO that knows what it’s doing.